Asma Riaz’s Post

Pediatric oncology is the field of medicine concerned with cancer in children.

Pediatric cancer treatments save lives, but they often lead to long-term complications for survivors. Dr. Kees-Jan Pronk, a pediatrician and researcher at Lund University, is focused on understanding these effects, especially in children treated for #leukemia and those undergoing stem cell transplants. “Cancer treatment of children can lead to complications later in life. It is important to think 30-40 years ahead,” says Kees-Jan Pronk, who splits his time between treating pediatric oncology patients at Skånes universitetssjukhus (Skåne University Hospital) and conducting research at Lund University. His work focuses on improving chemotherapy treatments and addressing complications like kidney damage and immune system recovery—aiming to increase survival rates while minimizing long-term health impacts for young #cancer survivors. At yesterday's Stem Cell Talk, Kees-Jan gave an insightful overview of his latest research at Lund Stem Cell Center, sharing important findings on how stem cells play a role in pediatric cancer treatment. His talk, “Are Stem Cells Still Relevant in Pediatric Disease?” attracted a strong turnout from students and researchers across the Medicinska fakulteten, Lunds universitet. Read more about his clinical research here: 🔗 https://lnkd.in/dmW89vPE #PediatricCancer #CancerResearch #StemCellTransplant #Paediatrics #MedicalResearch #Oncology #Hematology #StemCellTalk

Pediatric oncology is a specialized field dedicated to treating cancers that specifically affect children. Common childhood cancers include leukemia, neuroblastoma, brain cancers, lymphomas, Wilms' tumor, bone cancers, germ cell tumors, rhabdomyosarcoma, and retinoblastoma. 📌For More Information You Can Contact Us :- ✅Contact us:- +91 9371770341 ✅Email at:- [email protected] #pediatrichematology #pediatriconcologists #hematologysurgery #doctor #bonemarrow #healthcare #healthcare #hematology #hospital #microbiologie #bloodcancer

Every year, around 400,000 children are diagnosed with cancer, yet most drugs are designed for adults, leaving a critical gap in treatment options. The RACE for Children Act, passed in 2017, mandates that new oncology drugs be tested in pediatric patients when relevant. However, testing challenges persist due to the limited number of patients. Enter Charles River Laboratories, collaborating through the ITCC-P4 platform, prioritizes drugs using patient-derived xenograft (PDX) models. This innovative approach aims to enhance pediatric cancer treatment options, ultimately providing children with more effective therapies. #ChildhoodCancer #RACEforChildren #PediatricOncology #DrugDevelopment #ClinicalTrials #HealthInnovation #PDXModels

👧 Childhood cancer is a complex landscape encompassing various types, from leukemia to brain tumors. Understanding the signs and symptoms is crucial for early detection and intervention. 💪 Treatment approaches continue to evolve, offering hope and improved outcomes for young patients. From chemotherapy to immunotherapy, each modality plays a vital role in the fight against pediatric cancers. 📑 Read more at https://lnkd.in/dYpibbpZ 🌟 Let's spread knowledge, support, and advocacy for children battling cancer worldwide. #ChildhoodCancerAwareness #PediatricOncology #EarlyDetectionSavesLives 🎗️

CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope? CAR T-cell therapy, which involves collecting T cells, genetically re-engineering them to target specific antigens, and reinfusing them into patients, has shown promise beyond its initial focus on hematological cancers like B-cell non-Hodgkin lymphoma and multiple myeloma. Researchers are now exploring its potential in various other indications, including autoimmune diseases such as Systemic Lupus Erythematosus (SLE). While investigation of CAR T cells in human subjects with SLE has been limited, early data are encouraging. A recent study examining CAR T-cell infusion in patients with three autoimmune diseases, including SLE, demonstrated that the therapy was feasible, safe, and effective. This study, which included five young adults (aged 18-24) with SLE, reported sustained depletion of circulating B cells, control of Lupus Nephritis (LN), and a decrease in SLE Disease Activity Index scores, suggesting potential therapeutic benefits for SLE patients. Pubmed article: https://lnkd.in/dadHzGiJ

How Oncology Nurse Can Help You During Cancer? How Oncology Nurse Can Help You During Cancer? Comprehensive care for cancer patients is provided by oncology nurses. Beyond simply giving treatments, they are experts in providing holistic care, symptom management, and emotional aid. Shriram Nursing College trains its students to be experts in these areas so that they can have a major influence in patient care. In this blog, we will look at the ways in which oncology nurses assist cancer patients. #### Provide Expert Cancer Guidance Cancer patients can rely on the advice of oncology nurses educated at Shriram Nursing College. They educate patients about their condition, their treatment choices, and their journey’s expectations. These nurses provide patients with well-informed recommendations and personalized counsel by keeping themselves educated about the latest research and treatment breakthroughs. By listening to these professionals, cancer patients can feel empowered to take charge of their own treatment. #### Administer Precise Treatment Support Oncology nurses are known for their precision in administering treatment. Students learn the ins and outs of accurately administering immunotherapy, radiation, chemotherapy, and other cancer therapies at Shriram Nursing College. Dosage calculations, adverse reaction monitoring, and necessary dosage modifications are all part of this process. Making sure patients get the best care possible requires precise delivery of treatments in order to enhance efficacy while reducing negative effects. #### Monitor and Manage Symptoms Effectively To enhance a cancer patient’s quality of life throughout treatment, it is crucial to effectively manage symptoms. Managing side effects like nausea, exhaustion, and discomfort is one of the many topics covered by aspiring oncology nurses at Shriram Nursing College. In order to quickly alleviate these symptoms, they employ a variety of evaluation instruments and treatments. Oncology nurses play a crucial role in ensuring patients experience a higher quality of life during their treatment by aggressively treating side

This excellent review by Brivio et. al. describes naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia. Quoting from the abstract: "The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder of patients still dying from disease, and to reduce morbidity and mortality in those who can be cured with standard-of-care chemotherapy by replacing toxic chemotherapy elements while retaining cure rates. With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes. For B-cell precursor ALL, blinatumomab, an anti-CD19 bispecific antibody, has established its role in the consolidation treatment for both high- and standard-risk first relapse of ALL, in the presence of bone marrow involvement, and may also have an impact on the outcome of high-risk subsets such as infant ALL and Philadelphia chromosome-positive ALL. Inotuzumab ozogamicin, an anti-CD22 drug conjugated antibody, has demonstrated high efficacy in inducing complete remission in relapsed ALL, even in the presence of high tumor burden, but randomized phase III trials are still ongoing. For T-ALL the role of CD38-directed treatment, such as daratumumab, is gaining interest, but randomized data are needed to assess its specific benefit. These antibodies are currently being tested in patients with newly diagnosed ALL and may lead to major changes in the present paradigm of treatment of pediatric ALL. Unlike the past, lessons may be learned from innovations in adult ALL, in which more drastic changes are piloted that may need to be translated to pediatrics."

Challenges in Pediatric Oncology Treating a child is way more difficult than treating an Adult. Hence, Pediatric Oncology presents unique challenges that significantly differ from adult oncology. Annually, approximately 400,000 children and adolescents worldwide are diagnosed with cancer, with leukemia, brain cancers, lymphomas, and solid tumors like neuroblastoma and Wilms tumors being the most common types. One of the primary challenges is the disparity in survival rates between high-income and low- and middle-income countries (LMICs). In high-income countries, over 80% of children with cancer are cured, while in LMICs, this figure drops to less than 30%. Factors contributing to this disparity include delayed diagnosis, lack of access to accurate diagnostics, limited availability of essential medicines, and abandonment of treatment due to various socioeconomic barriers. Moreover, the treatment of pediatric cancer often involves addressing severe acute toxic effects and managing long-term health-related quality of life issues. The European Organisation for Research and Treatment of Cancer has developed tools to better measure these aspects, yet implementing these tools globally remains challenging. Environmental and genetic factors are one of the major reasons for pediatric cancer. Studies have shown links between parental exposure to ionizing radiation and increased cancer risks in offspring. Other factors include certain infections and parental exposure to tobacco smoke and pesticides. Addressing these challenges requires global collaboration to improve access to diagnostics, treatment, and supportive care in LMICs, alongside ongoing research to understand the environmental and genetic factors contributing to pediatric cancers. What's your take on this? Tell me in the comments below. #PediatricOncology #ChildhoodCancer #CancerAwareness #OncologyChallenges #GlobalHealth #HealthcareDisparities #CancerResearch #MedicalAdvancements #HealthEquity #CancerTreatment #PediatricCare #GlobalCollaboration #PublicHealth #MedicalResearch #HealthcareInnovation #CancerSupport #PediatricSurvival #CancerPrevention #OncologyResearch #MedicalCommunity #HealthcareAccess #CancerEducation #CancerSurvivorship #PediatricHealth #HealthCareChallenges

📃Scientific paper: Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry Abstract: Background Randomized controlled trials in pediatric kidney transplantation are hampered by low incidence and prevalence of kidney failure in children. Real-World Data from patient registries could facilitate the conduct of clinical trials by substituting a control cohort. However, the emulation of a control cohort by registry data in pediatric kidney transplantation has not been investigated so far. Methods In this multicenter comparative analysis, we emulated the control cohort ( n  = 54) of an RCT in pediatric kidney transplant patients (CRADLE trial; ClinicalTrials.gov NCT01544491) with data derived from the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry, using the same inclusion and exclusion criteria (CERTAIN cohort, n  = 554). Results Most baseline patient and transplant characteristics were well comparable between both cohorts. At year 1 posttransplant, a composite efficacy failure end point comprising biopsy-proven acute rejection, graft loss or death (5.8% ± 3.3% vs. 7.5% ± 1.1%, P  = 0.33), and kidney function (72.5 ± 24.9 vs. 77.3 ± 24.2 mL/min/1.73 m^2 P  = 0.19) did not differ significantly between CRADLE and CERTAIN. Furthermore, the incidence and severity of BPAR (5.6% vs. 7.8%), the degree of proteinuria (20.2 ± 13.9 vs. 30.6 ± 58.4 g/mol, P  = 0.15), and the key safety parameters such as occurrence of urinary tract infections (24.1% vs. 15.5%, P  = 0.10) were well comparable. Conclusions In conclusion, usage of Real-W... Continued on ES/IODE ➡️ https://etcse.fr/pBL ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.